Clinical Trial Update: Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating SHR-A1811 plus adebrelimab in untreated HR-negative/low and HER2-low breast cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-negative Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Untreated Early-stage or Locally Advanced Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING